Feature

Sen. Schumer backs federal decriminalization of marijuana


 

U.S. Sen. Chuck Schumer, the Senate majority leader, is cosponsoring legislation that would decriminalize marijuana at the federal level.

Marijuana leaves VladK213/Getty Images

The Cannabis Administration & Opportunity Act would allow the federal government to regulate and tax marijuana sales for the first time and would stop the federal prosecution of people for possessing and selling the drug, The New York Times reported. States could still make their own marijuana laws, however.

The bill calls for using money raised by taxing marijuana to help poor people and communities of color that have been unduly affected by marijuana laws.

Arrests and convictions for nonviolent marijuana offenses would be automatically expunged, The New York Times reported.

“The War on Drugs has been a war on people – particularly people of color,” a draft of the bill said, adding that the bill “aims to end the decades of harm inflicted on communities of color by removing cannabis from the federal list of controlled substances and empowering states to implement their own cannabis laws.”

But passage of the bill is highly uncertain because of strong Republican opposition in the Senate, where Democrats hold a narrow majority, according to The New York Times.

President Biden has not said he supports such legislation.

Sen. Schumer signaled his intentions when he spoke on April 20, the unofficial holiday for marijuana smokers.

“Hopefully, the next time this unofficial holiday of 4/20 rolls around, our country will have made progress in addressing the massive overcriminalization of marijuana in a meaningful and comprehensive way,” he said at the time, the newspaper reported.

Cosponsors were U.S. Sen. Cory Booker of New Jersey and U.S. Sen. Ron Wyden of Oregon, chairman of the Senate Finance Committee.

A version of this article first appeared on WebMD.com.

Recommended Reading

NSAIDs don’t make COVID-19 worse in hospitalized patients
MDedge Neurology
Not your ordinary neuropathy
MDedge Neurology
Combination therapy may benefit patients with migraine
MDedge Neurology
Physician convicted in buprenorphine scheme faces up to 20 years in prison
MDedge Neurology
A large proportion of migraine patients are not offered preventive treatment
MDedge Neurology
e-TNS device passes at-home test
MDedge Neurology
Chronic headache pain in veterans linked to suicide attempts
MDedge Neurology
Photobiomodulation: Evaluation in a wide range of medical specialties underway
MDedge Neurology
Novel NSAID–triptan drug effectively relieves migraine pain
MDedge Neurology
Updated consensus statement assesses new migraine treatments
MDedge Neurology